All In Biotech

Drug Trial Radar · NCT05302271

Phase IA and IB Study of AAVrh.10hFXN Gene Therapy for the Cardiomyopathy of Friedreich's Ataxia

Last checked: Nov 20, 2026Latest source record: Sep 28, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Recruiting

Status

Recruiting

Enrollment

25

Planned (sponsor's estimate)

Start

Feb 22, 2022

Primary completion

Dec 31, 2028

Study completion Dec 31, 2029

Sponsor

Lead sponsor
Weill Medical College of Cornell UniversityAcademic, hospital or other
Sponsor type
Academic, hospital or other
Collaborators
National Heart, Lung, and Blood Institute (NHLBI)
First posted
Mar 31, 2022

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 1
Allocation
Non randomized
Model
Sequential
Masking
None
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 12 years, up to 50 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The purpose of this study is to test the safety and preliminary efficacy of AAVrh.10hFXN to treat the cardiomyopathy associated with Friedreich's ataxia (FA). AAVrh.10hFXN is a serotype rh.10 adeno-associated virus gene transfer vector coding for Frataxin (FXN). The drug is administered intravenously. This is a phase 1, open label, dose escalation study with a total of 25 participants.

Conditions

  • Friedreich Ataxia
  • Cardiomyopathies
  • Cardiac Hypertrophy
  • Myocardial Fibrosis

Interventions

  • AAVrh.10hFXN, serotype rh.10 adeno-associated virus (AAV) gene transfer vector expressing the cDNA coding for human FXNBiological

    AAVrh.10hFXN will be administered intravenously.

  • PrednisoneDrug

    All participants will remain immunosuppression therapy with prednisone for a total of 14 weeks.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Safety of AAVrh.10hFXNTime frame: 5 Years

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • Weill Cornell Medicine

    New York, New York · Recruiting

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.